Physician profile
Patrick Lyons
NPI 1003218041
$3,862.18
in general payments reported to CMS, 2019-2025
29 companies · $934 in 2025
The $934 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $747 · 2022: $601 · 2023: $641 · 2024: $938 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.21 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.54 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $412.96 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $386.52 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $265.73 | 2021-2024 | Xarelto |
| Abbott Laboratories | $246.21 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $243.11 | 2022-2025 | |
| Glaxosmithkline, LLC. | $230.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $147.49 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $137.60 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Seqirus USA INC | $120.95 | 2022-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Astrazeneca Pharmaceuticals LP | $106.84 | 2024-2025 | Airsupra |
| Amarin Pharma, INC. | $91.06 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $83.56 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $81.47 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54.47 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $37.18 | 2022-2023 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $32.77 | 2021 | |
| Sanofi Pasteur INC. | $26.89 | 2022 | |
| Aimmune Therapeutics, INC. | $23.76 | 2025 | Vowst |
| Paratek Pharmaceuticals, INC. | $22.96 | 2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $21.99 | 2025 | Gemtesa |
| Lucid Diagnostics INC. | $18.07 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.76 | 2022 | |
| Dexcom, INC. | $17.32 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $16.59 | 2022 | |
| Eisai INC. | $16.29 | 2021 | |
| Dynavax Technologies Corporation | $16.24 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.23 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.